Email ID
Password
Scrip   
Ablynx's osteoporosis nanobody enters clinic
16 December 2009
Sukaina Virji

Ablynx of Belgium has began clinical testing of a fourth nanobody, ALX-0141, for the treatment of osteoporosis. ALX-0141 targets Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), a key regulator of bone resorption.

Overproduction of RANKL is implicated in a variety of degenerative...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36